Skip to main content

Adherence to Medication Regime

2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Astellas
AstellasChina - Shenyang
1 program
1
AdvagrafPhase 41 trial
Active Trials
NCT02251691Unknown90Est. Mar 2020
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
TasP using ART regimen as per Benin guidelinesPhase 41 trial
Active Trials
NCT02237027Completed361Est. Dec 2016
Servier
ServierFrance - Suresnes
1 program
Perindopril/Indapamide/Amlodipine fixed dose combinationN/A1 trial
Active Trials
NCT02655029Completed2,285Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Kite PharmaTasP using ART regimen as per Benin guidelines
AstellasAdvagraf
ServierPerindopril/Indapamide/Amlodipine fixed dose combination

Clinical Trials (3)

Total enrollment: 2,736 patients across 3 trials

NCT02237027Kite PharmaTasP using ART regimen as per Benin guidelines

Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin

Start: Oct 2014Est. completion: Dec 2016361 patients
Phase 4Completed
NCT02251691AstellasAdvagraf

Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant

Start: May 2014Est. completion: Mar 202090 patients
Phase 4Unknown
NCT02655029ServierPerindopril/Indapamide/Amlodipine fixed dose combination

Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination

Start: Nov 2015Est. completion: Dec 20162,285 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.